MX2024010388A - Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral del peptido-1 similar al glucagon y sus analogos. - Google Patents
Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral del peptido-1 similar al glucagon y sus analogos.Info
- Publication number
- MX2024010388A MX2024010388A MX2024010388A MX2024010388A MX2024010388A MX 2024010388 A MX2024010388 A MX 2024010388A MX 2024010388 A MX2024010388 A MX 2024010388A MX 2024010388 A MX2024010388 A MX 2024010388A MX 2024010388 A MX2024010388 A MX 2024010388A
- Authority
- MX
- Mexico
- Prior art keywords
- glucagon
- peptide
- analogs
- formulations
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920000642 polymer Polymers 0.000 title abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente invención se describe una composición farmacéutica que comprende un agente terapéuticamente activo, un potenciador de la absorción y un polímero que comprende una pluralidad de grupos alcalinos. El agente terapéuticamente activo es un péptido 1 similar al glucagón y/o un agonista del receptor del péptido 1 similar al glucagón. Una concentración del polímero en la composición es al menos el 10 por ciento en peso del peso total de la composición. El potenciador de la absorción es preferiblemente un ácido graso sustituido o no sustituido o una sal del mismo. En la presente invención se describen además métodos para tratar una afección tratable con el agente terapéuticamente activo, que comprende administrar por vía oral la composición farmacéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313365P | 2022-02-24 | 2022-02-24 | |
| PCT/IL2023/050197 WO2023161939A1 (en) | 2022-02-24 | 2023-02-23 | Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-1 and analogs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010388A true MX2024010388A (es) | 2024-09-04 |
Family
ID=87765066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010388A MX2024010388A (es) | 2022-02-24 | 2023-02-23 | Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral del peptido-1 similar al glucagon y sus analogos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4482514A1 (es) |
| JP (1) | JP2025506555A (es) |
| KR (1) | KR20240150507A (es) |
| CN (1) | CN119031930A (es) |
| AU (1) | AU2023226619A1 (es) |
| IL (1) | IL315204A (es) |
| MX (1) | MX2024010388A (es) |
| WO (1) | WO2023161939A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080153779A1 (en) * | 2005-02-01 | 2008-06-26 | Jun Liao | Gastric Retention and Controlled Release Delivery System |
| EP3326620B1 (en) * | 2010-12-16 | 2020-03-04 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid |
| US20180028622A1 (en) * | 2015-02-09 | 2018-02-01 | Entera Bio Ltd. | Treatment of osteoporosis |
-
2023
- 2023-02-23 EP EP23759469.2A patent/EP4482514A1/en active Pending
- 2023-02-23 JP JP2024550243A patent/JP2025506555A/ja active Pending
- 2023-02-23 CN CN202380034390.1A patent/CN119031930A/zh active Pending
- 2023-02-23 MX MX2024010388A patent/MX2024010388A/es unknown
- 2023-02-23 IL IL315204A patent/IL315204A/en unknown
- 2023-02-23 WO PCT/IL2023/050197 patent/WO2023161939A1/en active Application Filing
- 2023-02-23 KR KR1020247031759A patent/KR20240150507A/ko active Pending
- 2023-02-23 AU AU2023226619A patent/AU2023226619A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023226619A1 (en) | 2024-10-03 |
| EP4482514A1 (en) | 2025-01-01 |
| KR20240150507A (ko) | 2024-10-15 |
| IL315204A (en) | 2024-10-01 |
| JP2025506555A (ja) | 2025-03-11 |
| WO2023161939A1 (en) | 2023-08-31 |
| CN119031930A (zh) | 2024-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1505975B1 (en) | Compositions and method for treating infection in cattle and swine | |
| Weisler et al. | Comparison of bupropion and trazodone for the treatment of major depression | |
| EP1067927B1 (en) | Antioxidant stabilizer system for pharmaceutical formulations | |
| US20140275237A1 (en) | Beraprost isomer as an agent for the treatment of viral infection | |
| US20130109729A1 (en) | Pharmaceutical composition | |
| WO2013013143A1 (en) | Fixed dose combination of bimatoprost and brimonidine | |
| JP2007291067A (ja) | 医薬組成物 | |
| McKellar et al. | Pharmacokinetics of fenbendazole in dogs | |
| MX2024010389A (es) | Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral de hormona paratiroidea. | |
| MX2024010387A (es) | Formulaciones que comprenden polimero neutralizante de acido para administracion oral de agentes activos. | |
| US20060040905A1 (en) | Formulation of nefopam and its use in the treatment of pain | |
| MX2024010388A (es) | Formulaciones que comprenden un polimero neutralizante de acido para la administracion oral del peptido-1 similar al glucagon y sus analogos. | |
| US6008222A (en) | Method for oral administration of buspirone and nefazodone | |
| EP0524696A1 (en) | Oral compositions containing dapiprazole | |
| US12133845B2 (en) | Oromucosal solutions of zolpidem or pharmaceutically acceptable salts thereof | |
| US20050136127A1 (en) | Gastrointestinal compositions | |
| EP4183778A1 (en) | Analgesic and antipruritic pharmaceutical composition and application method therefor | |
| RU2024127870A (ru) | Композиции, содержащие кислотонейтрализующий полимер для перорального введения глюкагоноподобного пептида-1 и его аналогов | |
| EP1875913A1 (en) | Compositions and method for treating infection in cattle and swine | |
| EA045748B1 (ru) | Раствор золпидема или его фармацевтически приемлемой соли для оромукозного введения для лечения бессонницы | |
| Beech | Drug therapy of respiratory disorders | |
| AU2008321159B2 (en) | Liquid compositions comprising valsartan | |
| Suarez-Otero et al. | Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis | |
| JPH0662442B2 (ja) | 点鼻薬 | |
| NZ794535A (en) | Use of sublingual Dexmedetomidine for the treatment of agitation |